New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTCLDX, USPH, DXCM, INSM, IART, PBTH, AHS, CPHD, BIOS, ARNAOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
News For AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 31, 2015
07:36 EDTCPHDCepheid management to meet with JPMorgan
Meeting to be held in Chicago on August 4 hosted by JPMorgan.
July 30, 2015
17:00 EDTDXCMTandem Diabetes enters development agreements with DexCom
Subscribe for More Information
10:14 EDTIARTIntegra LifeSciences sees Q3 revenue $222M-$228M, consensus $221.54M
Subscribe for More Information
09:25 EDTCPHDLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard, along with Dr. Anami Patel and Dr. Nathan Ledeboer, discuss their perspectives on Point-of-Care molecular tests including the opportunity in virology / microbiology, the threat to traditional lab-based testing and point-of-care instruments on an Analyst/Industry conference call to be held on July 30 at 11 am.
06:25 EDTIARTIntegra LifeSciences sees FY15 adjusted EPS $3.00-$3.10, consensus $3.11
Sees FY15 revenue $870M-$885M, consensus $871.57M. "The new guidance range for 2015 continuing operations is consistent with our prior expectations. This new guidance reflects the removal of our spine business for the full year, which is expected to have a $0.20 dilutive impact to adjusted EPS, and the slight accretion we expect from the TEI acquisition, net of any financing impact we expect to incur in the second half of 2015," said Glenn Coleman, Integra's CFO. "We are maintaining our expectations for the underlying business excluding these transactions."
06:24 EDTIARTIntegra LifeSciences reports Q2 adjusted EPS 79c, consensus 72c
Subscribe for More Information
July 29, 2015
10:00 EDTIARTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3D Systems (DDD) upgraded to Neutral from Underperform at Longbow... AK Steel (AKS) upgraded to Outperform from Neutral at Macquarie... Ally Financial (ALLY) upgraded to Outperform from Neutral at Credit Suisse... Amazon.com (AMZN) upgraded to Buy from Hold at Stifel... Arrow Electronics (ARW) upgraded to Buy from Underperform at CLSA... Beacon Roofing (BECN) upgraded to Buy from Neutral at CL King... Citrix (CTXS) upgraded to Outperform at Baird... Commvault (CVLT) upgraded to Buy from Hold at Jefferies... FireEye (FEYE) upgraded on positive checks, business mdoel changes at Oppenheimer... Hibbett Sports (HIBB) upgraded to Neutral from Underperform at Sterne Agee CRT... Integra LifeSciences (IART) upgraded to Outperform at Raymond James... M/A-COM (MTSI) upgraded to Buy from Hold at Needham... Norsk Hydro (NHYDY) upgraded to Neutral from Underperform at Exane BNP Paribas... NuVasive (NUVA) upgraded to Outperform from Market Perform at Northland... SM Energy (SM) upgraded to Outperform from Market Perform at Raymond James... Scorpio Bulkers (SALT) upgraded to Buy from Hold at Deutsche Bank... Sirius XM (SIRI) upgraded to Buy from Hold at Wunderlich... Sprouts Farmers Markets (SFM) upgraded to Neutral from Underperform at Longbow... Supervalu (SVU) upgraded to Equal Weight from Underweight at Morgan Stanley... Waters (WAT) upgraded to Outperform from Market Perform at Wells Fargo... Wells Fargo (WFC) upgraded to Buy from Neutral at Guggenheim... Williams-Sonoma (WSM) upgraded to Overweight from Neutral at JPMorgan... YRC Worldwide (YRCW) upgraded to Strong Buy at Raymond James.
08:22 EDTARNAArena Pharmaceuticals begins Phase 2 trial of candidate for autoimmune diseases
Subscribe for More Information
07:39 EDTIARTIntegra LifeSciences upgraded to Outperform at Raymond James
Raymond James upgraded Integra LifeSciences to Outperform from Market Perform with a $73 price target. The firm said execution is improving, visibility is at a high, and the high margin product cycle coupled with capital deployment should improve sentiment and drive shares higher.
July 28, 2015
07:15 EDTCPHDCepheid product can beat competition, says Wells Fargo
Subscribe for More Information
July 27, 2015
07:19 EDTCPHDCepheid outlook remains positive, says Wells Fargo
Subscribe for More Information
July 24, 2015
10:00 EDTCPHDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Hold from Buy at Canaccord... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at Dougherty... CF Industries (CF) downgraded on nitrogen outlook at RBC Capital... Capital One (COF) downgraded to Neutral from Overweight at JPMorgan... Cepheid (CPHD) downgraded to Sell from Hold at Evercore ISI... Constant Contact (CTCT) downgraded to Neutral from Outperform at Baird... Equifax (EFX) downgraded to Neutral from Outperform at Baird... Hannover Re (HVRRY) downgraded to Underweight from Neutral at JPMorgan... IAMGOLD (IAG) downgraded to Underperform from Market Perform at Raymond James... MSA Safety (MSA) downgraded to Neutral from Accumulate at Global Hunter... MTU Aero (MTUAY) downgraded to Underperform from Buy at BofA/Merrill... Macy's (M) downgraded to Underweight from Neutral at Atlantic Equities... Sunesis (SNSS) downgraded to Hold from Buy at Cantor... Superior Drilling (SDPI) downgraded to Hold from Buy at Wunderlich... TrueCar (TRUE) downgraded to Equal Weight from Overweight at Stephens... United Rentals (URI) downgraded to Outperform from Top Pick at RBC Capital... WESCO (WCC) downgraded to Equal Weight from Overweight at Stephens.
07:00 EDTCPHDCepheid downgraded to Sell from Hold at Evercore ISI
Subscribe for More Information
05:55 EDTCPHDCepheid price target raised to $72 from $65 at Mizuho
Mizuho analyst Peter Lawson raised his price target for Cepheid to $72 following the company's Q2 results and reiterates a Buy rating on the name. Placements were strong across the board, which is an indication of strong future demand, Lawson tells investors in a post-earnings research note.
July 23, 2015
16:17 EDTCPHDCepheid sees FY15 EPS 25c-29c, consensus (44c)
Sees FY15 revenue $544M-$553M, consensus $551.29M.
16:16 EDTCPHDCepheid reports Q2 EPS ex-items (6c), consensus (21c)
Subscribe for More Information
July 21, 2015
15:42 EDTARNAArena Pharmaceuticals receives USPTO patent
Subscribe for More Information
July 20, 2015
07:33 EDTCPHDInternational AIDS Society to hold a conference
Subscribe for More Information
06:17 EDTCPHDMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
06:04 EDTIARTSeaSpine selling pressure may be over, says at Piper Jaffray
Piper Jaffray points out that shares of SeaSpine (SPNE) are down 15% since their spin-off from Integra LifeSciences (IART) on June 17. Piper attributes the weakness to non-fundamental selling by existing Integra shareholders and its analysis indicates that the worst of the selling pressure might be over. The firm keeps an Overweight rating on SeaSpine with a $24 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use